Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Mimedx (MDXG) Other financing activities (2016 - 2024)

Mimedx's Other financing activities history spans 6 years, with the latest figure at -$1.2 million for Q4 2024.

On a quarterly basis, Other financing activities changed N/A to -$1.2 million in Q4 2024 year-over-year; TTM through Sep 2025 was -$1.2 million, a 205.18% decrease, with the full-year FY2024 number at -$57000.0, changed N/A from a year prior.
Other financing activities hit -$1.2 million in Q4 2024 for Mimedx, down from $1.1 million in the prior quarter.
Over the last five years, Other financing activities for MDXG hit a ceiling of $6.5 million in Q3 2020 and a floor of -$3.3 million in Q4 2020.